Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05248230 · ClinicalTrials.gov registry record · Phase 2
4D-710 in Adult Patients With Cystic Fibrosis
A Phase 2 study of Cystic Fibrosis Lung, sponsored by 4D Molecular Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 20
- Study locations
NCT05248230: Recruiting Phase 2 study of Cystic Fibrosis Lung, sponsored by 4D Molecular Therapeutics.
NCT05248230 is a Phase 2 study of Cystic Fibrosis Lung that is actively recruiting participants, run by 4D Molecular Therapeutics. The registered enrollment target is 30 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05248230, a Phase 2 study of Cystic Fibrosis Lung, is actively recruiting participants, sponsored by 4D Molecular Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 1/2 multicenter, open-label, single dose trial of 4D-710 investigational gene therapy in adults with cystic fibrosis.
Primary Outcome
Safety and tolerability of 4D-710 following a single dose via inhalation, as assessed by incidence and severity of treatment emergent adverse events, serious adverse events, and dose limiting toxicities, including clinically significant changes from baseline to scheduled time points in safety parameters.
Conditions Studied
Interventions
- BIOLOGICAL 4D-710
Study Locations (20)
Florida
- University of Florida - Gainesville
- University of Miami Hospital - Miami
Massachusetts
- Massachusetts General Hospital - Boston
- Boston Children's Hospital - Boston
Ohio
- Rainbow Babies and Children's Hospital/University Hospitals Cleveland Medical Center - Cleveland
- Nationwide Children's Hospital - Columbus
Pennsylvania
- Penn State Health - Hershey
- The Hospital of the University of Pennsylvania - Philadelphia
Alabama
- University of Alabama Child Health Research Unit - Birmingham
Arizona
- The University of Arizona - Tucson
California
- University of California San Francisco - San Francisco
Colorado
- National Jewish Health - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-03-29 |
| Est. Completion | 2031-06 |
| Phase | Phase 2 |
What NCT05248230 shows while recruiting
NCT05248230 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Cystic Fibrosis Lung appearing as the primary indexed condition, and to 1 intervention - of which 4D-710 is the first listed.
NCT05248230 names 20 study sites across 16 states, led by Florida, Massachusetts, Ohio.
Frequently Asked Questions
What is clinical trial NCT05248230 about?
NCT05248230 is a clinical study titled "4D-710 in Adult Patients With Cystic Fibrosis". This is a Phase 1/2 multicenter, open-label, single dose trial of 4D-710 investigational gene therapy in adults with cystic fibrosis.
What is the current status of trial NCT05248230?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2022-03-29. Estimated completion is 2031-06.
What conditions does trial NCT05248230 study?
This clinical trial studies the following conditions: Cystic Fibrosis Lung.
What interventions are being tested in trial NCT05248230?
The interventions under investigation include: 4D-710 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05248230?
This trial is sponsored by 4D Molecular Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05248230 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05248230's enrollment target sits among peer trials
30 1582nd of 2000 higher than 333 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI